Scientists Predict.

The 21st century is the age of cellular therapy!

Globally recognised

Stem cells and regenerative medicine are expected to become the ‘golden key’ to break the code of life and open the door to the cure of major intractable diseases. More than 7,500 clinical studies on stem cells are being carried out worldwide, and 15 kinds of stem cell medicines are already on the market.

Yuanpin Bio, with R&D as the leader, has become a pioneer in the domestic biopharmaceutical industry.

The company implements the development strategy of ‘one body, two wings, three-wheel drive’, i.e. stem cell drug R&D and clinical transformation and application as the main body, and stem cell and immune cell storage business as the two wings, and the three-wheel drive of R&D, marketing and capital.

Unique hardcore technology route, focusing on major intractable diseases

Since 2004, Professor Wang Jian's technical team has conducted nearly 40,000 clinical studies using human umbilical cord mesenchymal stem cell preparations and human amniotic membrane mesenchymal stem cell preparations. Professor Xue Zhigang's team has used single-cell transcriptome sequencing technology to analyse cell subpopulations and their mechanism of action, and its results have been published in Nature and other top international journals.

Aiming at the frontiers of science and technology in the world, and oriented to the treatment of major intractable diseases, the company adopts the company's unique single-cell subpopulation fractal and high-throughput sequencing technology, and discovers that mesenchymal stem cells with different genetic backgrounds and from different tissues are composed of different subpopulations of stem cells, and different subpopulations of cells play a role in the treatment of different diseases by means of different action mechanisms, through the source of the company's proprietary preparation process technology, the company has produced stem cells enriched with specific subpopulations of cells. Through our proprietary preparation technology, we can produce stem cell preparations enriched with specific cell subpopulations for the treatment of specific diseases, which have unique therapeutic effects.

The company is working on the following projects.

Basic research: Professor Wang Jian, Professor Xue Zhigang team with academicians and experts to carry out 40,000 cases of clinical research, the effect is remarkable.

Technology line: based on single-cell sequencing technology subpopulation typing, focusing on major intractable diseases.

Green channel: governments at all levels have opened up a green channel for drug approval, accelerating the company's stem cell drug declaration.